European Companies Search Engine
EU funding (€3,664,174): ENdoThelial macRophage Alliance In Neuroinflammation Hor1 May 2019 EU Research and Innovation programme "Horizon"
Overview
Text
ENdoThelial macRophage Alliance In Neuroinflammation
Neurological diseases cause enormous suffering and a great economic burden. Almost 20 million Europeans are affected by the most frequently occurring and disabling disease entities, such as stroke, Alzheimer’s disease (AD), or multiple sclerosis (MS), and these numbers do not include the large group of rare diseases that affect the CNS. Overall, the annual costs for patient care amount to 400 billion Euros. Common features of many neurological diseases are a vascular pathology with impaired blood-brain barrier (BBB) function or with reduced blood flow and inflammatory changes. As the two are often associated, disentangling their intricate and mutual relationship is a major task for translational neuroscience that could improve the treatment of many neurological diseases. At the cellular level, key players are brain endothelial cells as the building blocks of cerebral vessels and macrophages as the main inflammatory cells of the brain. Recent discoveries indicate that endothelial cells and brain macrophages are in intimate contact and closely interact. However, there is a huge gap of knowledge regarding the specific mode and the consequences of these interactions. Therefore, in-depth analyses of the molecular mechanisms involved are essential to identify and understand key features of macrophage-endothelial cross-talk, and exploitation of this information for the development of treatments of neurological diseases. ENTRAIN will undertake this task, using novel and emerging technologies, such as cutting-edge chemoproteomics, unique genetic and viral tools for targeting of defined cell populations, and high resolution intravital imaging. By characterising the pas de deux of endothelial cells and macrophages at the functional and morphological level, we will lay the foundation for better therapies for neurological diseases. The results will impact on the understanding of neuroinflammation, but also on the rarefaction of vessels.
Funded Companies:
| Company name | Funding amount |
| BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | €250,905 |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | €281,277 |
| HELSINGIN YLIOPISTO | €280,806 |
| HUN-REN Kiserleti Orvostudomanyi Kutatointezet | €229,715 |
| Institut National de la Sante et de la Recherche Medicale | €274,802 |
| Istituto Di Ricerche Farmacologiche Mario Negri | €261,500 |
| MIMETAS B.V. | €265,620 |
| STICHTING AMSTERDAM UMC | €265,620 |
| Universita Degli Studi Di Brescia | €261,500 |
| UNIVERSITAET BERN | €281,277 |
| UNIVERSITAET MUENSTER | €252,788 |
| UNIVERSITAETSKLINIKUM FREIBURG | €252,788 |
| UNIVERSITAET zu LUEBECK | €505,577 |
Source: https://cordis.europa.eu/project/id/813294
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim a. Rhein, Germany.
The visualizations for "BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG - EU funding (€3,664,174): ENdoThelial macRophage Alliance In Neuroinflammation"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
